|
| Advances in immunotherapy for triple-negative breast cancer |
| Hits 1000 Download times 715 Received:July 20, 2020 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2020.11.23 |
| Key Words
triple-negative breast cancer;immunotherapy;cancer vaccine;immune checkpoint |
| Author Name | Affiliation | E-mail | | ZHAO Weipeng | Department of Breast Internal Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Medical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Treatment, Ministry of Education, Tianjin 300060, China | | | SUN Linlin | Department of Breast Internal Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Medical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Treatment, Ministry of Education, Tianjin 300060, China | | | TONG Zhongsheng | Department of Breast Internal Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Medical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Treatment, Ministry of Education, Tianjin 300060, China | tongzhongsheng_on@163.com |
|
| Abstract
|
| Triple-negative breast cancer lacks endocrine and anti-human epidermal growth factor receptor 2 (HER2) therapeutic targets because its receptor estrogen receptor (ER),progesterone receptor (PR) and HER2 are all negative. At present,surgery,chemotherapy and radiotherapy are still the main treatments. Compared with these conventional treatment schemes,new treatment methods such as breast cancer immunotherapy are also lagging behind. The strategies of immunotherapy for triple-negative breast cancer include enhancing the antigen presenting ability of dendritic cells and activating the function of effector T cells,inhibiting regulatory T cells and myelogenous suppressor cells,and up-regulating related cytokines,reversing tumor inhibitory microenvironment and promoting anti-tumor immune response. Thereby exerting the function of killing tumor cells. The antibody therapy of programmed death receptor 1 (PD-1)/its ligand PD-L1 in solid tumors has made gratifying achievements,and a small sample of clinical trials have been done in patients with triple-negative breast cancer. The immunotherapy of triple-negative breast cancer has attracted more and more attention,and Chinese medicine has also made many attempts in triple-negative breast cancer. This paper summarizes the present situation and prospect of immunotherapy of triple-negative breast cancer. |
|
|
|
|
|
|
|
